ArticleBMC cancer2025
Impact of metabolic and nutritional disorders on the synergy between radiotherapy and immunotherapy in non-small-cell lung cancer.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- The Role of Nutritional and Inflammatory Indices in Predicting Prognosis in Older Adults Undergoing Radiotherapy for Lung Cancer: NIRT-LC Study.Journal of clinical medicine · 2026Article
- Article
- Predictive value of the systemic immune-inflammation index and geriatric nutritional risk index on the efficacy of immunotherapy and survival prognosis in advanced non-small cell lung cancer: a retrospective study.American journal of cancer research · 2026Article
- Correction: Impact of metabolic and nutritional disorders on the synergy between radiotherapy and immunotherapy in non-small-cell lung cancer.BMC cancer · 2025Article
- Immunometabolism in cancer: a systemic perspective.Frontiers in immunology · 2025Review
Corrections and comments
- Erratum issued
Authors and funding
8 authors.
Funding
Abstract
backgroundPatient conditions including metabolic and nutritional status were reported to be prognostic or predictive biomarkers of anti-cancer treatment, while little attention has been paid to its association with the synergistic effect of radiotherapy (RT) and immune checkpoint inhibitors (ICIs).
methodsMetastatic non-small-cell lung cancer (mNSCLC) patients who received concurrent RT and ICIs between 2018 and 2023 were included in this study. In addition, mNSCLC patients treated with ICIs alone were enrolled to confirm the synergetic effect of RT and ICIs. Clinicopathological, metabolic and nutritional factors were collected to analyze their influence on progression-free survival (PFS), overall survival and abscopal control time. Abdominal CT was used to obtain body composition data including abdominal obesity and muscle mass.
resultsA total of 96 mNSCLC patients who received RT concurrent with ICIs were included, and a synergistic effect of significantly improved PFS was observed when compared with patients treated with ICIs alone. Among patients undergoing concurrent RT and ICIs, both total adipose area(HR = 2.81,P = 0.029) and prognosis nutritional index (HR = 0.24, P<0.001) were confirmed as independent positive prognostic markers for PFS. Later-line of immunotherapy (HR = 3.67, P = 0.006), low visceral-to-subcutaneous ratio (VSR, HR = 5.53, P = 0.002), high total adipose area (HR = 5.21, P = 0.0016) and high prognostic nutritional index (HR = 0.24, P = 0.002) were independent risk factors for abscopal progression. Then, we established a scoring system consisting of metabolic and nutritional factors to stratify patients into three groups. Patients with non-visceral obesity and good nutrition status have the longest PFS and abscopal control survival, while patients with poor nutritional status regardless of body composition represent the worst prognosis.
conclusionMetabolic and nutritional status, particularly the combined assessment of body composition and nutritional index, serves as a valuable predictor for the synergistic efficacy of concurrent RT and ICIs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.